Shares in Sorrento Therapeutics (SRNE) spiked 10.51% in Tuesday’s trading after the company released positive Phase 1b Study results evaluating safety and MTD (maximum tolerated dose) of epidural resiniferatoxin (RTX) injection to treat intractable cancer pain.A majority of patients reported meaningful pain reduction of 30% or more from baseline, and no dose limiting toxicities were reported.The data was presented at the 14th Annual Pain Therapeutics Summit held virtually from September 21 to 22, 2020.“We are extremely encouraged by the results of this initial study. Even in patients with high levels of pain, RTX given via an epidural injection has been …read more
Source:: Yahoo Finance
